Teva Pharmaceutical Industries Limited (IL:TEVA)
TASE:TEVA
Want to see IL:TEVA full AI Analyst Report?
TEVA Stock Chart & Stats
9672.00
0.44(0.56%)
At close: 4:00 PM EST
9672.00
0.44(0.56%)
Day’s Range― - ―
52-Week Range5,305.00 - 11,350.00
Previous CloseN/A
Volume1.42M
Average Volume (3M)1.92M
Market Cap
₪111.05B
Enterprise Value51.07B
Total Cash (Recent Filing)₪3.78B
Total Debt (Recent Filing)₪17.07B
Price to Earnings (P/E)23.9
Beta0.56
Next Earnings
Jul 29, 2026EPS Estimate
176.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.38
Shares Outstanding1,164,638,700
10 Day Avg. Volume1,312,069
30 Day Avg. Volume1,917,294
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.58
Price to Sales (P/S)1.94
P/FCF Ratio14.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪13,708.00Price Target Upside41.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)6.43
Revenue Forecast (FY)₪48.66B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundTeva has moved from multi-year losses to sustained positive margins (TTM ~9% net, ~13% EBIT). Durable margin improvement indicates operational fixes, better product mix, and stronger cost control — supporting reinvestment capacity, resilience to cyclical shocks, and a more predictable earnings base over the medium term.
Improving Cash GenerationMeaningful free cash flow growth and a ~$3.7B cash position enhance Teva's ability to fund transformation, R&D, and targeted M&A without immediate reliance on capital markets. Persistent FCF supports deleveraging and capital allocation flexibility, making balance-sheet repair and shareholder returns more feasible over 2–6 months and beyond.
Innovative Portfolio ExpansionA faster-growing, higher-margin innovative portfolio materially diversifies Teva away from low-margin generics. Durable growth in branded products (AUSTEDO, UZEDY, AJOVY) supports margin sustainability, reduces revenue cyclicality tied to LOE events, and creates a structural path toward higher operating margins and recurring cash generation.
Bears Say
Elevated LeverageTeva's elevated leverage reduces financial flexibility and increases vulnerability to profit volatility or higher rates. Even with improving cash flow, debt levels constrain the company's ability to invest, pursue large M&A, or accelerate buybacks until net-debt/EBITDA moves meaningfully below current levels, extending balance-sheet repair needs.
Generics Revenue HeadwindsStructural pressures in the legacy generics franchise—loss of high-revenue molecules and pricing competition—create ongoing top-line volatility. A material decline in generics reduces the low-margin volume cushion, forcing reliance on newer, concentrated sources of growth while making revenue consistency and forecasting more difficult.
Acquisition-related Near-term P&L HitTreating the Emalex acquisition as an asset deal with large upfront expensing materially pressures 2026 operating results. While strategic long-term, the accounting-driven P&L hit and incremental OpEx compress near-term margins and earnings metrics, delaying visible accretion until the product contributes revenue in 2027–2028.
Teva News
TEVA FAQ
What was Teva Pharmaceutical Industries Limited’s price range in the past 12 months?
Teva Pharmaceutical Industries Limited lowest stock price was 5305.00 and its highest was 11350.00 in the past 12 months.
What is Teva Pharmaceutical Industries Limited’s market cap?
Teva Pharmaceutical Industries Limited’s market cap is ₪111.05B.
When is Teva Pharmaceutical Industries Limited’s upcoming earnings report date?
Teva Pharmaceutical Industries Limited’s upcoming earnings report date is Jul 29, 2026 which is in 39 days.
How were Teva Pharmaceutical Industries Limited’s earnings last quarter?
Teva Pharmaceutical Industries Limited released its earnings results on Apr 29, 2026. The company reported 157.6 earnings per share for the quarter, beating the consensus estimate of 142.9 by 14.7.
Is Teva Pharmaceutical Industries Limited overvalued?
According to Wall Street analysts Teva Pharmaceutical Industries Limited’s price is currently Undervalued.
Does Teva Pharmaceutical Industries Limited pay dividends?
Teva Pharmaceutical Industries Limited pays a Quarterly dividend of 8.5 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical Industries Limited dividends here
What is Teva Pharmaceutical Industries Limited’s EPS estimate?
Teva Pharmaceutical Industries Limited’s EPS estimate is 176.3.
How many shares outstanding does Teva Pharmaceutical Industries Limited have?
Teva Pharmaceutical Industries Limited has 1,164,638,700 shares outstanding.
What happened to Teva Pharmaceutical Industries Limited’s price movement after its last earnings report?
Teva Pharmaceutical Industries Limited reported an EPS of 157.6 in its last earnings report, beating expectations of 142.9. Following the earnings report the stock price went up 9.759%.
Which hedge fund is a major shareholder of Teva Pharmaceutical Industries Limited?
Currently, no hedge funds are holding shares in IL:TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited operates as a prominent global pharmaceutical firm, involved in the research, development, manufacturing, marketing, and distribution of generic, specialized, and biopharmaceutical products throughout North America, Europe, and other international regions. The company's diverse portfolio encompasses sterile preparations, hormonal therapies, high-potency drugs, and cytotoxic substances, supplied in a wide array of dosage forms such as tablets, capsules, injectable solutions, inhalants, oral liquids, transdermal patches, topical ointments, and creams. Furthermore, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). A significant portion of its research and product development is concentrated on the central nervous system, pain management, respiratory illnesses, and oncology. Leading products for the central nervous system include Copaxone, utilized for relapsing multiple sclerosis; AJOVY, an option for migraine prevention; and AUSTEDO, prescribed for tardive dyskinesia and chorea linked to Huntington's disease. Within the respiratory domain, addressing asthma and chronic obstructive pulmonary disease, Teva offers products like ProAir, QVAR, various Digihaler and RespiClick formulations, along with BRALTUS and CINQAIR/CINQAERO. Their oncology division features treatments such as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. The company also collaborates with MedinCell on the creation and commercialization of multiple extended-release injectable products, including a risperidone suspension designed for individuals with schizophrenia. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
13,708.00
▲(41.73% Upside)